Dendritic cell immunotherapy for patients with resected pancreatic cancer
Phase 1
Completed
- Conditions
- <p>Pancreatic cancer, alvleesklierkanker, pancreascarcinoom</p>10015674
- Registration Number
- NL-OMON28791
- Lead Sponsor
- Erasmus Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
Exclusion Criteria
A potential subject who meets any of the following criteria will be excluded from participation in this study:
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The main goal of this study is to determine feasibility of MesoPher maintenance therapy in pancreatic cancer patients who underwent a radical tumor resection and received standard of care.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary objectives are safety assessment after dendritic cell vaccination and the determination of an immunological response in blood with emphasis on T lymphocytes.</p><br>